Illumina, Inc. $ILMN Holdings Decreased by Sumitomo Mitsui Trust Group Inc.

Key Points

• Sumitomo Mitsui Trust Group cut its stake in Illumina by 2.7% to 1,254,595 shares (about $164.55M); institutional investors now own roughly 89.42% of the company.
• Other large funds made material moves — Capital World Investors added 3.33M shares (+20%) to hold ~19.98M shares, Nordea increased holdings by 2,792.2% to 944,500 shares, Thrivent boosted its position 1,558%, and Pacer and MFS opened new multi‑million‑dollar positions.
• Analysts have an average "Hold" rating with a $129.69 consensus target even as Illumina beat Q4 estimates (EPS $1.35 vs. $1.26) and set FY2026 guidance of $5.05–$5.20; the company will report Q1 results on April 30, a potential near‑term catalyst (insider Patricia Leckman recently sold 2,370 shares).

Sumitomo Mitsui Trust Group Inc. decreased its holdings in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 2.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,254,595 shares of the life sciences company's stock after selling 35,215 shares during the quarter. Sumitomo Mitsui Trust Group Inc. owned 0.82% of Illumina worth $164,553,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of ILMN. Capital World Investors grew its holdings in shares of Illumina by 20.0% during the third quarter. Capital World Investors now owns 19,976,850 shares of the life sciences company's stock valued at $1,897,178,000 after buying an additional 3,331,542 shares in the last quarter. Nordea Investment Management AB grew its holdings in shares of Illumina by 2,792.2% during the fourth quarter. Nordea Investment Management AB now owns 944,500 shares of the life sciences company's stock valued at $124,145,000 after buying an additional 911,843 shares in the last quarter. Thrivent Financial for Lutherans grew its holdings in shares of Illumina by 1,558.0% during the second quarter. Thrivent Financial for Lutherans now owns 728,755 shares of the life sciences company's stock valued at $69,528,000 after buying an additional 684,802 shares in the last quarter. Pacer Advisors Inc. purchased a new position in shares of Illumina during the third quarter valued at $61,663,000. Finally, Massachusetts Financial Services Co. MA purchased a new position in shares of Illumina during the fourth quarter valued at $73,532,000. Hedge funds and other institutional investors own 89.42% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on ILMN. TD Cowen reiterated a "hold" rating on shares of Illumina in a report on Wednesday, January 7th. JPMorgan Chase & Co. lowered their target price on Illumina from $130.00 to $120.00 and set a "neutral" rating on the stock in a research note on Friday, February 6th. Wall Street Zen upgraded Illumina from a "buy" rating to a "strong-buy" rating in a research note on Saturday, February 14th. Robert W. Baird set a $137.00 target price on Illumina in a research note on Friday, February 6th. Finally, Evercore set a $150.00 target price on Illumina in a research note on Friday, February 6th. Six equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, Illumina presently has an average rating of "Hold" and a consensus target price of $129.69.

Key Stories Impacting Illumina

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Analysts highlight Illumina’s strong earnings-surprise history and say the company currently has the characteristics that make another quarterly beat likely — a bullish near-term earnings catalyst that can support the stock ahead of the April 30 report. Will Illumina (ILMN) Beat Estimates Again in Its Next Earnings Report? Zacks: Will Illumina (ILMN) Beat Estimates Again?
• Neutral Sentiment: Illumina confirmed it will report Q1 2026 results after the close on Thursday, April 30, with a management conference call scheduled — a clear near-term event that could drive volatility depending on revenue/guide vs. expectations. Illumina to Announce First Quarter 2026 Financial Results
• Neutral Sentiment: Market coverage notes recent share-price strength (outperformance since Oct‑2025) but also that Illumina still lags broader market measures on some timeframes — useful context for momentum and relative-performance trades. MarketWatch: Illumina stock rises, still underperforms market
• Neutral Sentiment: A valuation/peer piece compares Illumina to Regeneron as potential value plays in the biomedical/genetics space — useful for investors weighing sector alternatives but not an immediate directional catalyst. REGN or ILMN: Which Is the Better Value Stock Right Now?
• Negative Sentiment: A Seeking Alpha analysis argues that competitive threats (new platforms, pricing pressure) are an ongoing headwind and may already be reflected in the stock — a cautionary take that can temper upside expectations and increase sensitivity to execution. Illumina: Competitive Threats Priced In
• Negative Sentiment: A recent “3 Reasons to Avoid ILMN” article outlines concerns (valuation after the run, execution/risks) that may be driving some profit‑taking and cautious positioning despite recent strong results. 3 Reasons to Avoid ILMN and 1 Stock to Buy Instead

Insider Activity

In other news, SVP Patricia Leckman sold 2,370 shares of the company's stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $116.18, for a total transaction of $275,346.60. Following the completion of the sale, the senior vice president owned 16,321 shares in the company, valued at approximately $1,896,173.78. This represents a 12.68% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 0.17% of the company's stock.

Illumina Stock Performance

Shares of NASDAQ ILMN opened at $120.93 on Monday. The business's 50-day moving average price is $123.95 and its two-hundred day moving average price is $123.65. The company has a debt-to-equity ratio of 0.55, a current ratio of 2.08 and a quick ratio of 1.72. Illumina, Inc. has a one year low of $69.83 and a one year high of $155.53. The company has a market capitalization of $18.37 billion, a P/E ratio of 22.19, a price-to-earnings-growth ratio of 2.32 and a beta of 1.49.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its earnings results on Thursday, February 5th. The life sciences company reported $1.35 EPS for the quarter, beating analysts' consensus estimates of $1.26 by $0.09. Illumina had a return on equity of 31.04% and a net margin of 19.57%.The firm had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.10 billion. During the same quarter in the previous year, the company posted $0.95 earnings per share. The business's quarterly revenue was up 5.0% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. Analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Illumina Company Profile

Illumina, Inc NASDAQ: ILMN is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company's product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.